Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC